Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02RVC
|
||||
| Former ID |
DIB015589
|
||||
| Drug Name |
PPI-383
|
||||
| Indication | HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] | Phase 1 | [1] | ||
| Company |
Presidio pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | Hepatitis C virus NS5B polymerase | Target Info | Inhibitor | [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01928147) A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients. U.S. National Institutes of Health. | ||||
| REF 2 | 1173 IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5B NON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJOR HCV GENOTYPES. Journal of Hepatology Volume 56, Supplement 2, April 2012, Pages S464. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.